Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib versus platinum-based chemotherapy in first-line EGFR exon 20 insertion-mutated advanced non-squamous NSCLC
NL-OMON53471Phase 3Not yet recruiting
- Sponsor
- ArriVent BioPharma
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by ArriVent BioPharma. Primary endpoint: Progression-free survival by blinded independent central review. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON53471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53471.